Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 131 to 140 of 279 total matches.
In Brief: Prevention of Measles
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025 (Issue 1730)
to neomycin (M-M-R II and Priorix) or
hypersensitivity to gelatin (M-M-R II).
VACCINE ADVERSE EFFECTS — Pain ...
According to the Centers for Disease Control (CDC),
as of April 24 there have been 844 confirmed cases of
measles in the US in 2025; 11% of cases have resulted
in hospitalization and 3 patients have died. The majority
of cases (96%) have been in unvaccinated persons or in
those whose vaccination history was unknown
Med Lett Drugs Ther. 2025 Jun 9;67(1730):94-5 doi:10.58347/tml.2025.1730d | Show Introduction Hide Introduction
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis.1 The
GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the
gonadotropin-releasing hormone (GnRH) receptor
antagonist elagolix, the estrogen estradiol, and the
progestin norethindrone acetate copackaged with
elagolix alone, has been approved by the FDA for oral
treatment of heavy menstrual bleeding associated
with uterine leiomyomas (fibroids) in premenopausal
women. It is the first product to be approved in the
US for this indication. Elagolix (Orilissa) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis. The
GnRH receptor antagonist...
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
in ≥20% of patients) were pain
and erythema at the injection site, malaise, and myalgia.
Among subjects ...
The FDA has licensed MenQuadfi (Sanofi Pasteur),
a quadrivalent polysaccharide conjugate vaccine
that uses tetanus toxoid as a protein carrier, for
prevention of invasive meningococcal disease caused
by Neisseria meningitidis serogroups A, C, W, and Y
(MenACWY) in persons ≥2 years old.
Prevention and Treatment of Monkeypox
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
and at least every 10 years for exposure to less
virulent orthopoxviruses
Common adverse effects Pain ...
An outbreak of monkeypox has recently spread around
the globe and across the US. Updated information
about the current outbreak is available from the CDC.
A New RSV Vaccine (mResvia) for Adults ≥60 Years Old
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
).
▶ Adverse Effects: Most common are injection-site pain, axillary
swelling or tenderness, fatigue, headache ...
TThe FDA has licensed mResvia (Moderna), an
mRNA respiratory syncytial virus (RSV) vaccine, for
prevention of lower respiratory tract disease (LRTD)
caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this
indication. Two recombinant RSV vaccines, Arexvy
and Abrysvo, are also available for prevention of RSV
LRTD. Arexvy is approved for use in adults ≥50 years
old. Abrysvo is approved for use in adults ≥60 years
old and in pregnant women to prevent RSV LRTD in
their infants.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-8 doi:10.58347/tml.2024.1713d | Show Introduction Hide Introduction
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
often with Arexvy
than placebo in the pivotal clinical trial included
injection-site pain (60.9% vs ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
Adolescents and young adults who experience
acute chest pain, shortness of breath, or palpitations
after ...
On June 25, 2021, the FDA added a warning to the
Fact Sheets for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) about an increased risk of
myocarditis and pericarditis following administration
of the vaccines.
In Brief: Shingrix for Immunocompromised Adults
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
, fever, GI symptoms,
and injection-site pain, redness, and swelling are
common. Severe local reactions ...
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;
Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
,
musculoskeletal pain, pruritus, diarrhea, rash, pyrexia,
and nausea. Infusion-related reactions and severe ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
effects: diarrhea is most common (lowering the dose may help), abdominal pain, flatulence, abdominal ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721e | Show Introduction Hide Introduction